Adaptive Radiation Boost for Rectal Cancer

The goal of this clinical trial is to find out if giving extra adaptive radiation therapy after standard chemoradiation treatment is safe and helpful for people with rectal cancer. The main questions the study aims to answer are: * Can this approach help target the most aggressive cancer cells more accurately, while protecting nearby healthy tissue? * Can it reduce the side effects that people may experience during treatment? Participants will: * First receive standard treatment: radiation (45 Gy in 25 sessions) along with a chemotherapy pill called capecitabine. * Then get extra radiation

Trial Details

NCT ID
NCT07221058
Phase
PHASE1
Sponsor
Fox Chase Cancer Center
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Adaptive Radiotherapy Boost
Locations (sample)
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Subjects must have histologically or cytologically confirmed rectal adenocarcinoma.
  • Subjects must have T2-3, N0-1, M0 rectal cancer. Staging will be done by MRI pelvis and CT chest and abdomen with contrast. PET-CT will be an accep…
  • Subjects must be willing to undergo MRI scans.
  • Age ≥18 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →